Vizora日本語

SuzukenSUZUKEN CO.,LTD.9987東証プライム卸売業FY ending Mar 2026, consolidated, J-GAAP

Which Suzuken businesses make the profit?

Revenue by business segment, and the profit each one keeps.

Revenue by geography

Geographic revenue reported in annual filings

No geographic revenue breakdown was disclosed.

※ Segment figures include inter-segment sales and do not sum to the company total

Revenue and profit mix

FY ending Mar 2026

Revenue mix

Profit mix (profitable segments)

The Pharmaceutical Distribution Business accounts for 94% of revenue and 87% of profit.

  • The Specialty Drug Contract Distribution Business
    Revenue 0.3%Profit 3.2%Difference +2.9 ptMargin 17.0%Specialty Trading & Wholesale
  • The healthcare product development business
    Revenue 0.5%Profit 2.3%Difference +1.8 ptMargin 7.0%Pharmaceuticals
  • The Healthcare-Related Services Business
    Revenue 1.0%Profit 3.5%Difference +2.5 ptMargin 5.2%CRO & Clinical Testing
  • The community healthcare and nursing care support business
    Revenue 3.8%Profit 4.3%Difference +0.5 ptMargin 1.6%Drugstores & Pharmacies
  • The Pharmaceutical Distribution Business
    Revenue 94.5%Profit 86.7%Difference -7.7 ptMargin 1.3%Specialty Trading & Wholesale

Calculated from disclosed figures; listed by margin. Difference = profit share − revenue share (percentage points). Segment revenues may include inter-segment sales and may not sum to company revenue.

Business growth × margin

X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.

Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.

Segment history (JPY millions)

SegmentRevenue CAGRFY ending Mar 2022FY ending Mar 2023FY ending Mar 2024FY ending Mar 2025FY ending Mar 2026
The Pharmaceutical Distribution Business+3.4%5y2,099,0820.7%2,177,0301.2%2,248,4151.4%2,263,1351.4%2,349,3861.3%
The Pharmaceutical Manufacturing Business—12,2376.4%10,64811.5%———
The Insurance Pharmacy Business—88,7862.6%87,7182.3%———
The Healthcare-Related Services Business-7.0%5y39,0065.7%28,1964.0%22,5282.4%24,3324.3%24,6295.2%
The healthcare product development business+0.8%3y—11,64113.4%11,89213.4%11,67616.4%11,9337.0%
The community healthcare and nursing care support business-1.4%3y—97,9602.6%97,4431.7%94,3991.4%93,9221.6%
The Specialty Drug Contract Distribution Business+4.4%2y——6,2139.2%6,40713.2%6,77517.0%

Top: revenue. Bottom: operating margin.

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第80期(2025/04/01－2026/03/31)

    ID S100YFRU2026-06-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第79期(2024/04/01－2025/03/31)

    ID S100W3YI2025-06-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第78期(2023/04/01－2024/03/31)

    ID S100TQTQ2024-06-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第77期(2022/04/01－2023/03/31)

    ID S100R3L52023-06-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第76期(令和3年4月1日－令和4年3月31日)

    ID S100OCGE2022-06-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第75期(令和2年4月1日－令和3年3月31日)

    ID S100LN0D2021-06-25Open

Extracted from XBRL: 53 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image